The FLAURA2 study recently showed the efficacy of osimertinib in combination with chemotherapy compared to osimertinib monotherapy in patients with locally advanced or metastatic NSCLC with frequent EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.